|Videos|November 10, 2014
AZD9291 in Advanced NSCLC
Author(s)Susan Galbraith, MD, PhD
Susan Galbraith, MD, PhD, provides an overview of the ongoing phase I/II AURA study.
Advertisement
Clinical Pearls
Susan Galbraith, MD, PhD, head, Oncology Innovative Medicine, AstraZeneca, provides an overview of the ongoing phase I/II AURA study, which aims to evaluate AZD9291 for patients previously treated with an EGFR TKI with advanced non-small cell lung cancer (NSCLC) with the T790M mutation.
- The confirmed overall response rate was 70% in patients treated with 80 mg of AZD9291.
- Responses are durable – median PFS is 9.6 months. Today, the only option for this group of patients is chemotherapy, which elicits PFS of 3-4 months.
- AZD9291 is associated with reduced rates of rash and diarrhea compared with chemotherapy.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Tentative Approval to New Cabozantinib Capsule Formulation
2
FDA Clears Rituximab Biosimilar, Expanding Options for B-Cell Malignancies
3
In Squamous NSCLC, Cemiplimab Data Pulled the Room Away From Dual Checkpoint Blockade
4
Real-World Analysis Explores GLP-1 Use and Overall Survival
5